Exhibit 99.1

                        PharmaFrontiers Appoints Gregory
           Bailey, M.D. and Scott Seaman, CPA, to Board of Directors

    THE WOODLANDS, Texas--(BUSINESS WIRE)--April 17, 2006--
PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the
development and commercialization of cell therapies, today announced
the appointment of Gregory H. Bailey, M.D., and Scott B. Seaman, CPA
and CFP, to PharmaFrontiers' board of directors. The Company also
announced that Brooks Boveroux, Tony Kamin and Terry Wesner have
stepped down from their positions on the board in connection with the
closing of the $23 million financing.
    David B. McWilliams, chief executive officer of PharmaFrontiers,
commented, "We are very pleased to welcome Greg and Scott to the board
where they will join Paul Frison and me. The wealth of diversified
experience in finance and healthcare that these individuals bring will
be very significant in helping the Company pursue the future
milestones for our T-Cell and stem cell technologies."
    McWilliams continued, "We would also like to thank Brooks, Tony
and Terry for helping PharmaFrontiers advance to this stage of our
development as we will soon begin a major Phase IIb trial for multiple
sclerosis using Tovaxin(TM)."

    Gregory H. Bailey, M.D.

    Gregory H. Bailey, M.D., is managing director, Investment Banking
of MDB Capital located in Santa Monica, California. He joined the firm
in 2004 with a focus on medical technology. Dr. Bailey has over
fifteen years' experience in investment banking and has also founded
several companies. Along with comprehensive experience in healthcare,
finance and medicine Dr. Bailey also brings to the board of directors
an extensive involvement in corporate governance. Dr. Bailey has
served on multiple public company boards of directors.
    Dr. Bailey was a practicing physician for ten years and holds a
M.D. degree from the University of Western Ontario.

    Scott B. Seaman

    Scott B. Seaman is the executive director of the Albert and
Margaret Alkek Foundation of Houston, a private foundation primarily
supporting institutions in the Texas Medical Center in Houston. For
the last twenty years he has held various financial positions in
companies affiliated with the Alkek family interests. He is also
chairman and president of Impact Composite Technology Ltd and a
general partner of the Global Hedged Equity Fund LP. Mr. Seaman had
prior experience with Arthur Andersen & Co. and is a member of the
American Institute of Certified Public Accountants.

    About PharmaFrontiers Corp.

    PharmaFrontiers' strategy is to develop and commercialize cell
therapies to treat several major disease areas such as multiple
sclerosis, rheumatoid arthritis, pancreatic and cardiac conditions.
PharmaFrontiers has exclusive license from Baylor College of Medicine
for individualized cell therapies that will be starting an FDA Phase
IIb clinical trial to evaluate effectiveness in treating MS. The
company also holds the exclusive worldwide license for an autologous T
cell vaccine for rheumatoid arthritis from the Shanghai Institutes for
Biological Sciences (SIBS), Chinese Academy of Sciences of the
People's Republic of China. The company also holds the exclusive
worldwide license from the University of Chicago, through its prime
contractor relationship with Argonne National Laboratory, for patents
relating to the use of adult pluripotent stem cells derived from
patients' own circulating blood.

    Safe Harbor Statement

    This press release contains "forward-looking statements,"
including statements about PharmaFrontiers' growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that are
not historical facts or information. These forward-looking statements
are based on management's current assumptions and expectations and
involve risks, uncertainties and other important factors, specifically
including those relating to PharmaFrontiers' ability to obtain
additional funding, develop its stem cell technologies, achieve its
operational objectives, and obtain patent protection for its
discoveries, that may cause PharmaFrontiers' actual results to be
materially different from any future results expressed or implied by
such forward-looking statements. PharmaFrontiers undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.


    CONTACT: PharmaFrontiers Corp.
             Lynne Hohlfeld, 281-719-3421
             lhohlfeld@pharmafrontierscorp.com
             or
             Investor Relations Contacts:
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             or
             Bruce Voss, 310-691-7100
             bvoss@lhai.com